The tumor suppressor gene TP53: implications for cancer management and therapy

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The p53 protein is a critical tumor suppressor involved in anti-proliferative responses to cellular stress.
• TP53 gene inactivation is common in human cancers, leading to compromised genetic stability and treatment resistance.
• Restoring p53 function is a key goal for effective cancer therapy.

Purpose of the Study:

• To review current genetic and pharmacological strategies for restoring or controlling p53 function in cancer patients.
• To discuss the mechanisms and potential of these approaches for cancer treatment.
• To explore the role of mutant TP53 detection in cancer management.

Main Methods:

• Review of genetic interventions, including viral gene transfer (retroviral, adenoviral) and selective oncolytic viruses (e.g., ONYX-015).
• Analysis of pharmacological approaches using small molecules (e.g., CP-31388, PRIMA-1), peptides, and antibody fragments to modulate p53 activity.
• Discussion of TP53 mutation detection for early diagnosis, prediction, and prognosis.

Main Results:

• Genetic approaches like wild-type TP53 re-expression have shown limited success, but oncolytic viruses targeting p53-deficient cells are promising.
• Pharmacological strategies aim to reactivate wild-type p53 or restore function to mutant forms.
• Detection of mutant TP53 offers potential as a biomarker for cancer management.

Conclusions:

• Restoring p53 function represents a significant therapeutic avenue for various cancers.
• Diverse strategies, from gene therapy to small molecule drugs, are being developed to target p53 pathways.
• Further research into these approaches holds promise for improving cancer treatment efficacy and patient outcomes.